title: Outcomes of patients with stage IVA esophageal cancer (Japanese classification) treated with definitive chemoradiotherapy.
abstract: OBJECTIVE
  To evaluate treatment outcomes of chemoradiotherapy for patients with stage IVA esophageal cancer and to estimate prognostic factors.
  
  
  METHODS
  Patients with stage IVA esophageal cancer treated with chemoradiotherapy between April 2003 and March 2009 were evaluated. Patients received concurrent chemoradiotherapy comprising cisplatin plus 5-fluorouracil and 61.2 Gy of radiotherapy. Therapeutic response, overall survival time, and toxicity were examined and statistical evaluation was performed.
  
  
  RESULTS
  Ninety patients were treated using chemoradiotherapy. Among these, 71 patients (78.9 %) received the complete course of chemoradiotherapy. Seventeen patients (18.9 %) showed complete response, 64 patients (71.1 %) had partial response, 7 patients (7.8 %) experienced no change, and 2 patients (2.2 %) exhibited progressive disease. Mean duration of follow-up was 16.1 months (range 2-88 months). Median overall survival was 12.8 months. Two- and 3-year overall survival rates were 35.1 and 18.6 %, respectively. Severe hematological toxicities included Grade 3 leukopenia in 33 patients (36.7 %). Treatment-related death was estimated to have occurred in 7 patients. Performance status and body weight loss were identified as significant prognostic factors.
  
  
  CONCLUSIONS
  Our treatment outcomes appeared similar to those of previous studies that used chemoradiotherapy for advanced esophageal cancer. This treatment is useful for stage IVA esophageal cancer.
authors: Department of Radiology and Radiation Oncology, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita, Akita, 010-8543, Japan. anbai@doc.med.akita-u.ac.jp
authors: Akira
authors: A
authors: Anbai
authors: Makoto
authors: M
authors: Koga
authors: Satoru
authors: S
authors: Motoyama
authors: Mario
authors: M
authors: Jin
authors: Hiroyuki
authors: H
authors: Shibata
authors: Manabu
authors: M
authors: Hashimoto
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage; D059248:Chemoradiotherapy / Q000009:adverse effects / Q000401:mortality; D002945:Cisplatin / Q000008:administration & dosage; D004938:Esophageal Neoplasms / Q000628:therapy*; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D011879:Radiotherapy Dosage; D016896:Treatment Outcome; D015431:Weight Loss
chemical_list: D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D002945:Cisplatin; D005472:Fluorouracil
references: N Engl J Med. 1992 Jun 11;326(24):1593-8
references: 1584260
references: Int J Radiat Oncol Biol Phys. 2009 Oct 1;75(2):357-63
references: 19735863
references: Jpn J Clin Oncol. 2004 Oct;34(10):615-9
references: 15591460
references: Int J Clin Oncol. 2012 Feb;17(1):48-54
references: 21607829
references: Radiat Med. 1998 Nov-Dec;16(6):461-8
references: 9929147
references: JAMA. 1999 May 5;281(17):1623-7
references: 10235156
references: Radiother Oncol. 2008 Jun;87(3):398-404
references: 18405987
references: Jpn J Clin Oncol. 2001 Aug;31(8):375-81
references: 11574630
references: J Clin Oncol. 2002 Mar 1;20(5):1167-74
references: 11870157
references: Jpn J Clin Oncol. 1996 Oct;26(5):310-5
references: 8895670
references: Ann Surg. 1994 Sep;220(3):364-72; discussion 372-3
references: 8092902
references: Cancer. 1981 Jan 1;47(1):207-14
references: 7459811
references: Semin Oncol. 1994 Aug;21(4):483-92
references: 8042046
references: J Clin Oncol. 1999 Sep;17(9):2915-21
references: 10561371
references: Cancer. 1994 Jul 1;74(1):4-11
references: 8004581